News
Video
Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium
Caron A. Jacobson, MD, discusses the significance of a real-world follow-up analysis of liso-cel in which safety and efficacy findings in patients with comorbidities and others who were not eligible for clinical trials were consistent with those studies.
EP: 1.The Expanding Utility of CAR T-Cell Therapy in LBCL
EP: 2.Sequencing With CAR T-Cell Therapy for LBCL
EP: 3.CAR T-Cell Therapy as a Second-Line Treatment for LBCL
EP: 4.Understanding Malignancy Risks With the Use of CAR T-cell Therapies
Now Viewing
EP: 5.Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium
EP: 6.Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL
EP: 7.The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL
EP: 8.Bridging Therapy With CAR T-Cell Therapy in LBCL
EP: 9.The Future of CAR T-Cell Therapy in LBCL
EP: 10.Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology
Related Videos
Related Content
